The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Impact of hemochromatosis gene mutations on cardiac status in doxorubicin‐treated survivors of childhood high‐risk leukemia
Open accessAbstract
BACKGROUND: Doxorubicin is associated with progressive cardiac dysfunction, possibly through the formation of doxorubicin‐iron complexes leading to free‐radical injury. The authors determined the frequency of hemochromatosis (HFE) gene mutations associated with hereditary hemochromatosis and their relationship with doxorubicin‐associated cardiotoxicity in survivors of childhood high‐risk acute lymphoblastic leukemia. METHODS: Peripheral blood was tested for 2 common HFE allelic variants: C282Y and H63D. Serum cardiac troponin‐T (cTnT) and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP), which are biomarkers of cardiac injury and cardiomyopathy, respectively, were assayed during therapy. Left ventricular (LV) structure and function were assessed with echocardiography. RESULTS: A total of 184 patients had DNA results for at least 1 variant, and 167 had DNA results for both: 24% carried H63D and 10% carried C282Y. Heterozygous C282Y genotype was associated with multiple elevations in cTnT concentrations (P = .039), but not NT‐proBNP. At a median of 2.2 years (range, 1.0 years–3.6 years) after diagnosis, the mean Z‐scores for LV fractional shortening (−0.71 [standard error (SE), 0.25]; P = .008), mass (−0.84 [SE, 0.17]; P < .001), and end‐systolic (−4.36 [SE, 0.26], P < .001) and end‐diastolic (−0.68 [SE, 0.25]; P = .01) posterior wall thickness were found to be abnormal in children with either allele (n = 32). Noncarriers (n = 63) also were found to have below‐normal LV mass (−0.45 [SE, 0.15]; P = .006) and end‐systolic posterior wall thickness (−4.06 [SE, 0.17]; P < .001). Later follow‐up demonstrated similar results. CONCLUSIONS: Doxorubicin‐associated myocardial injury was associated with C282Y HFE carriers. Although LV mass and wall thickness were found to be abnormally low overall, they were even lower in HFE carriers, who also had reduced LV function. Screening newly diagnosed cancer patients for HFE mutations may identify those at risk for doxorubicin‐induced cardiotoxicity. Cancer 2013;119:3555–3562.. © 2013 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ebb, D., Meyers, P., Grier, H., Bernstein, M., Gorlick, R., Lipshultz, S. E., Krailo, M., Devidas, M., Barkauskas, D. A., Siegal, G. P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4546 · Cited by 243
Self-citation
Cited by
Regulated cell death pathways in doxorubicin-induced cardiotoxicity
Christidi, E., & Brunham, L. R. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03614-x · Cited by 684
Prevention of Anthracycline-Induced Cardiotoxicity
Vejpongsa, P., & Yeh, E. T. H. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.06.1167 · Cited by 671
Lipshultz, S. E., Adams, M. J., Colan, S. D., Constine, L. S., Herman, E. H., Hsu, D. T., Hudson, M. M., Kremer, L. C., Landy, D. C., Miller, T. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e3182a88099 · Cited by 612
Self-citationAnthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention
Henriksen, P. A. (2018) · Heart · doi:10.1136/heartjnl-2017-312103 · Cited by 536
Individual Prediction of Heart Failure Among Childhood Cancer Survivors
Chow, E. J., Chen, Y., Kremer, L. C., Breslow, N. E., Hudson, M. M., Armstrong, G. T., Border, W. L., Feijen, E. A. M., Green, D. M., Meacham, L. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.1373 · Cited by 280
Metadata
- Authors
- Lipshultz, S. E., Lipsitz, S. R., Kutok, J. L., Miller, T. L., Colan, S. D., Neuberg, D. S., Stevenson, K. E., Fleming, M. D., Sallan, S. E., Franco, V. I., Henkel, J. M., Asselin, B. L., Athale, U. H., Clavell, L. A., Michon, B., Laverdiere, C., Larsen, E., Kelly, K. M., & Silverman, L. B.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2013-07-16
- Volume
- 119
- Issue
- 19
- Pages
- 3555-3562
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1669909471
- Cited by
- 158
- References
- 1
- FWCI
- 11.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of hemochromatosis gene mutations on cardiac status in doxorubicin‐treated survivors of childhood high‐risk leukemia. https://app.cochat.ai/papers/10.1002/cncr.28256
- The paper
- Lipshultz, S. E., Lipsitz, S. R., Kutok, J. L., Miller, T. L., Colan, S. D., Neuberg, D. S., Stevenson, K. E., Fleming, M. D., Sallan, S. E., Franco, V. I., Henkel, J. M., Asselin, B. L., Athale, U. H., Clavell, L. A., Michon, B., Laverdiere, C., Larsen, E., Kelly, K. M., & Silverman, L. B. (2013). Impact of hemochromatosis gene mutations on cardiac status in doxorubicin‐treated survivors of childhood high‐risk leukemia. Cancer. https://doi.org/10.1002/cncr.28256
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.